HUMEDIX CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33,000 KRW | +3.77% |
|
-1.49% | -2.22% |
| Sales 2023 * | 154B 112M | Sales 2024 * | 179B 130M | Capitalization | 343B 249M |
|---|---|---|---|---|---|
| Net income 2023 * | 29B 21.05M | Net income 2024 * | 39B 28.31M | EV / Sales 2023 * | 2.22 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.91 x |
| P/E ratio 2023 * |
12.2
x | P/E ratio 2024 * |
8.99
x | Employees | 248 |
| Yield 2023 * |
1.89% | Yield 2024 * |
1.89% | Free-Float | 55.09% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.77% | ||
| 1 week | -1.49% | ||
| Current month | +14.38% | ||
| 1 month | +11.11% | ||
| 3 months | +15.18% | ||
| 6 months | -5.31% | ||
| Current year | -2.22% |
1 week
31 000.00
33 450.00
1 month
27 500.0035 800.00
Current year
26 750.0035 800.00
1 year
26 000.0044 500.00
3 years
17 850.0044 600.00
5 years
10 000.0044 600.00
10 years
10 000.0088 134.94
| Managers | Title | Age | Since |
|---|---|---|---|
Jin-Hwan Kim
CEO | Chief Executive Officer | 58 | - |
Moon-Jung Lim
CTO | Chief Tech/Sci/R&D Officer | 61 | - |
Sung-Tae Yoon
BRD | Director/Board Member | 59 | 15-03-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Tae Yoon
BRD | Director/Board Member | 59 | 15-03-19 |
Joong-Sik Koh
BRD | Director/Board Member | 69 | - |
Moon-Jung Lim
CTO | Chief Tech/Sci/R&D Officer | 61 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 33,000 | +3.77% | 87 681 |
| 24-04-25 | 31,800 | -2.90% | 75,009 |
| 24-04-24 | 32,750 | +1.39% | 71,279 |
| 24-04-23 | 32,300 | -1.52% | 88,243 |
| 24-04-22 | 32,800 | -0.30% | 119,790 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Humedix Co., Ltd. is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals .The Companyâs main products consist of preparations for the treatment of arthritis, prescription drugs, medicament for the eyes, active pharmaceutical ingredients (APIs), as well as cosmetics and others. The Company distributes its products within domestic market and to overseas markets
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
31,800
KRW
Average target price
56,000
KRW
Spread / Average Target
+76.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.22% | 240M | |
| +26.09% | 653B | |
| +27.00% | 556B | |
| -6.53% | 354B | |
| +20.43% | 331B | |
| +2.73% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.33% | 144B |
- Stock Market
- Equities
- A200670 Stock
